Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia

Habsah Aziz, Chow Y. Ping, Hamidah Alias, Nurul-Syakima Ab Mutalib, Rahman Jamal
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

We report a patient who presented with simultaneous T-lymphoblastic lymphoma, focal myeloid proliferation, and cutaneous cytotoxic T-cell lymphoma refractory to chemotherapy. The presence of myeloid and lymphoid lineages prompted genetic and molecular studies. A PDGFRA rearrangement was identified in all compartments: cutaneous, lymph node, and bone marrow. Treatment with imatinib resulted in an excellent response in cutaneous and systemic disease. We report the first case of a mature cutaneous T-cell lymphoma with PDGFRA rearrangement, expanding the spectrum of neoplasms associated with this genetic abnormality. Our case ...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news
July 20, 2018 -- The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at ASCO 2018. Author: obr Added: 07/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) at ASCO 2018 Author: obr Added: 07/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
FRIDAY, July 20, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. " The use of Tibsovo is associated...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
(MedPage Today) -- Approved therapies now available for IDH1- and IDH2-mutant disease
Source: MedPage Today Public Health - Category: American Health Source Type: news
Condition:   Leukaemia Intervention:   Drug: SAR440234 Sponsor:   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Drugs & Pharmacology | Genetics | Leukemia